On September 9, 2025, Jefferies raised its price target on Fortrea Holdings Inc. to $9.50 from $7.00, while maintaining a 'Hold' rating on the shares. This adjustment reflects a more optimistic outlook on the company's prospects.
The primary driver for this revised sentiment was the observed strengthening in biotech funding. An improved funding environment for biotechnology companies is generally beneficial for contract research organizations like Fortrea, as it can lead to increased research and development spending.
This analyst action suggests a positive re-evaluation of Fortrea's potential revenue generation from the biotech sector. The increased price target indicates a belief in the company's ability to capitalize on improving market conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.